Evogene (NASDAQ:EVGN) Stock Price Passes Below 200-Day Moving Average – Should You Sell?

Evogene Ltd. (NASDAQ:EVGN) crossed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $2.40 and traded as low as $1.46. Evogene shares last traded at $1.48, with a volume of 42,424 shares.

Wall Street Analyst Weigh In

Separately, StockNews.com assumed coverage on Evogene in a research report on Friday. They set a “sell” rating for the company.

Evogene Stock Up 4.5 %

The business has a 50-day moving average of $1.57 and a 200-day moving average of $2.37. The stock has a market cap of $8.31 million, a price-to-earnings ratio of -0.35 and a beta of 1.29.

Evogene (NASDAQ:EVGN) last announced its quarterly earnings results on Thursday, November 21st. The biotechnology company reported ($1.31) earnings per share (EPS) for the quarter. Evogene had a negative net margin of 314.43% and a negative return on equity of 109.05%.

Institutional Investors Weigh In On Evogene

An institutional investor recently bought a new position in Evogene stock. Jane Street Group LLC purchased a new stake in Evogene Ltd. (NASDAQ:EVGN) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 21,345 shares of the biotechnology company’s stock, valued at approximately $40,000. Jane Street Group LLC owned approximately 0.40% of Evogene as of its most recent filing with the SEC. Institutional investors own 10.40% of the company’s stock.

Evogene Company Profile

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.